Mandate

Vicore Pharma Holding acquires INIM Pharma

Vinge has advised the shareholders of INIM Pharma in connection with the sale of the company to Vicore Pharma Holding, which is listed on First North.

INIM Pharma develops a new local treatment of severe and unusual forms of lung disease such as idiopathic lung fibrosis. 

The acquisition is performed as an issue in kind corresponding to a dilution of 35.8 per cent. HealthCap VII LP owns 85 per cent of INIM and following the acquisition HealthCap VII LP will hold approximately 30.4 per cent of the shares in Vicore Pharma Holding.

The transaction is subject to customary closing conditions.

Vinge’s team consisted of Johan Winnerblad, Kristina Ekberg, Jesper Schönbeck, Rikard Lindahl and Malin Malm Waerme.
 

Related

Vinge advises Baseload Capital in connection with an investment from Google

Vinge has advised Baseload Capital Holding AB in connection with securing an investment from Google.
April 16, 2025

Vinge advises Acrinova in connection with the sale of properties

Vinge advises Acrinova AB (publ) in connection with its sale of properties with an underlying property value of SEK 1.4 billion.
April 15, 2025

Vinge has advised Visa in connection with its investment in Mynt AB

Vinge has advised Visa in connection with its investment in the Swedish fintech company Mynt AB ("Mynt"). The investment, which is part of Mynt's announced Series B funding round, underscores Visa's commitment to supporting innovative fintech solutions and improving payment experiences for businesses across Europe.
April 14, 2025